Johnson & Johnson (NYSE:JNJ) Shares Purchased by RKL Wealth Management LLC

RKL Wealth Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 30.9% in the 4th quarter, Holdings Channel reports. The fund owned 31,025 shares of the company’s stock after acquiring an additional 7,320 shares during the quarter. RKL Wealth Management LLC’s holdings in Johnson & Johnson were worth $4,487,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $213,000. Swedbank AB raised its stake in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after buying an additional 111,570 shares in the last quarter. Walkner Condon Financial Advisors LLC increased its stake in Johnson & Johnson by 4.4% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 2,843 shares of the company’s stock valued at $461,000 after purchasing an additional 121 shares in the last quarter. Bridgewater Advisors Inc. increased its stake in Johnson & Johnson by 34.0% in the 3rd quarter. Bridgewater Advisors Inc. now owns 31,286 shares of the company’s stock valued at $5,009,000 after purchasing an additional 7,934 shares in the last quarter. Finally, David J Yvars Group purchased a new position in Johnson & Johnson in the 3rd quarter valued at approximately $205,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $166.81 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock’s fifty day simple moving average is $152.95 and its 200-day simple moving average is $156.30. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $401.61 billion, a price-to-earnings ratio of 25.08, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on JNJ. Citigroup dropped their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Leerink Partners dropped their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Wells Fargo & Company dropped their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.